Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H30N6O3 |
Molecular Weight | 462.5441 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=CC=CC(=C1)C2=CC=C3C(N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C)=N2
InChI
InChIKey=JUSFANSTBFGBAF-IRXDYDNUSA-N
InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1
Vistusertib (AZ-2014) is a dual inhibitor of mTORC1/mTORC2 which was developed by AstraZeneca for the treatment of cancer. The drug is under clinical development (phase II) in patients with Renal Carcinoma, Squamous Non Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Meningioma, Breast cancer and Gastric cancer, either alone or in combination therapy. Vistusertib penetrates blood-brain barrier.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2221341 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23375793 |
210.0 nM [IC50] | ||
Target ID: mTORC2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23375793 |
78.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 21.3174 uM] | ||||
likely | ||||
likely | ||||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29790111/ |
no | |||
yes [IC50 10.684 uM] | ||||
yes [IC50 15.0916 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
major | ||||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sample Use Guides
Renal Carcinoma: patients receive 50mg twice a day. Squamous Non Small Cell Lung Cancer: patients receive study treatment consisting of a single weekly paclitaxel infusion (80 mg/m2) on Day 1 of each week and twice daily 50 mg doses of vistusertib on the first 3 days each week for 6 weeks. Diffuse Large B-Cell Lymphoma: patients receive 125mg of vistusertib twice daily - 2 days on 5 days off in a 28 day cycle. Gastric Adenocarcinoma: patients receive 50mg of vistusertib twice dayly, 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24311635
Glioblastoma stem-like cells were treated with vistusertib (2 uM) and radiation to investigate the effects of the drug on the radiosensitivity of cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
||
|
NCI_THESAURUS |
C2201
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000174944
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
EF-07
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
DB11925
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
C88329
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL1078983
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
0BSC3P4H5X
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
25262792
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
10158
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
DTXSID20143584
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY | |||
|
1009298-59-2
Created by
admin on Sat Dec 16 10:31:18 GMT 2023 , Edited by admin on Sat Dec 16 10:31:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY